Mass Tort Lead Generation Guide 2026

Multidistrict litigation now accounts for roughly 68% of the entire federal civil docket, up from just 29% a little over a decade ago. Nearly 200,000 cases are currently pending across more than 150 active MDLs, spanning pharmaceuticals, medical devices, chemical exposure, and even consumer technology claims.

For plaintiff firms, that growth represents an enormous opportunity — and an enormous amount of competition. If your firm’s calendar isn’t full of qualified mass tort clients, the problem usually isn’t a shortage of leads. It’s a mismatch between how mass tort leads need to be generated, qualified, and converted, and the general personal injury playbook most firms still default to. Here’s a complete breakdown of what actually works in 2026.

What Makes Mass Tort Lead Generation Different

Mass tort marketing gets lumped in with general personal injury lead generation, but the two require very different strategies.

A general PI campaign can cast a relatively wide net. Car accidents happen constantly, and the qualification bar is comparatively simple. Mass tort claims don’t work that way. Each tort has its own specific product, exposure window, diagnosis requirements, and evidentiary needs. A talc claimant needs a specific cancer diagnosis and documented product use. Someone pursuing a hair relaxer claim needs a matching diagnosis and years of usage history. PFAS cases require documented exposure to a specific water source or occupation. Vague, one-size-fits-all messaging doesn’t just underperform in mass tort marketing. In fact, it actively works against you, generating high lead volume filled with people who will never qualify.

That means every mass tort campaign needs to target one tort at a time, speak directly to that tort’s specific criteria, and reach the demographics and geographies where real claimants are most likely to exist.

​

The 2026 Mass Tort Landscape: What’s Active Right Now

The mix of active litigation shifts constantly, but several categories are driving the bulk of new filings and marketing activity heading into the second half of 2026:

Pharmaceutical litigation: GLP-1 weight-loss drug claims (Ozempic, Wegovy, Mounjaro, and related medications) are among the fastest-growing dockets, with bellwether trials approaching.

Medical devices: Cases involving implanted devices like the Bard PowerPort and Paragard IUD continue to expand, with bellwether trials proceeding through 2026 and into 2027.

Chemical and environmental exposure: PFAS (“forever chemicals”) litigation, particularly firefighting foam claims, has grown into one of the largest active dockets.

Consumer products: The talcum powder litigation against Johnson & Johnson remains the single largest active mass tort by case count, and chemical hair relaxer claims continue building steadily.

Technology and social media: A newer but rapidly developing category, with claims tied to platform design and youth mental health harms moving through both MDL and school-district bellwether proceedings.

Each of these sits at a different point in its litigation lifecycle, which matters enormously for how you should be marketing to it right now.

Marketing by Litigation Phase

Mass tort marketing isn’t static. The right message changes as a case moves through its lifecycle, and campaigns that ignore this waste significant budget.

Pre-litigation. Awareness is often still low. Marketing here needs to be educational: explaining what happened, who’s affected, and why it matters, without overpromising outcomes. This phase typically has the least competition and the lowest cost per lead, but claimant volume is also lower since fewer people know they may have a claim.

Active litigation. Awareness rises sharply, along with competition and cost per lead. Messaging should get more specific. For instance, citing real qualification criteria, referencing the MDL by name where appropriate, and creating urgency around statute of limitations deadlines, as these vary significantly by state and by claim type.

Settlement phase. Volume often spikes as news coverage increases, but so does the number of firms competing for the same claimants. Speed and intake efficiency become the deciding factor. Many claimants sign with whichever firm reaches them first and makes the process feel clear and trustworthy.

Building a Mass Tort Marketing Channel Mix

Digital advertising (paid search and paid social) remains the fastest way to reach people actively searching for information about a specific product or diagnosis. Plus, it allows tight targeting by geography, age, and interest.

Content marketing and SEO matter more in mass tort than almost any other legal vertical. Claimants frequently research their diagnosis and product history extensively before ever contacting an attorney. Well-structured, tort-specific content also positions your firm to be surfaced by AI search tools, which a growing number of claimants now consult before searching directly.

Television still drives meaningful volume for mass tort, especially in high-value, high-awareness litigation. However, production and airtime costs put it out of reach for many independent firms without outsourcing support.

Direct mail can be highly effective for torts in which affected populations are identifiable through public records or claims data, particularly for device- and exposure-based claims.

Social media has become both a channel and, increasingly, a subject: a wave of litigation is now targeting the platforms themselves. Firms marketing social media harm claims need to be especially precise about qualification criteria, given how broad and emotionally charged this topic is.

Streamlining Your Intake Process

Generating leads is only half the equation. A firm that can’t move qualified claimants through intake quickly loses cases to competitors who can.

A strong mass tort intake process needs:

Clear, written qualification criteria your intake team can apply consistently, not general instincts about who “sounds like” a good case

Training on the specific tort, including the diagnosis, product, and exposure requirements that separate a qualified claimant from an unqualified one

Fast disqualification for leads that don’t meet criteria, so staff time goes toward claimants who can actually sign

A clear handoff process to get qualified leads in front of an attorney for signature quickly, especially during high-competition settlement phases

Documentation tracking for medical records, product use verification, and other evidence required to support the claim later

Firms that treat intake as an afterthought routinely lose winnable cases to slower internal processes rather than to weaker marketing.

Measuring What Actually Matters: Cost Per Signed Case

Cost per lead is the easiest number to track and the least useful one on its own. A campaign generating leads at $40 each is a bad deal if only 2% ever sign, and a campaign generating leads at $200 each can be a great deal if 40% convert into retained cases.

The number that should drive every decision about your mass tort marketing budget is cost per signed case, factored against the expected value of that case type. Track lead-to-signed-case conversion by source and by campaign, not just in aggregate, so you can see clearly which channels and vendors are actually producing business rather than just producing volume.

In-House Generation vs. Outsourcing

Some firms build mass tort lead generation entirely in-house by running their own digital campaigns, managing their own intake, and owning the full process. This offers maximum control but requires real internal expertise in a fast-changing, tort-specific advertising landscape, along with the budget to compete for ad placement against national firms.

Outsourcing to an experienced mass tort lead generation partner is the more common path. A qualified vendor should pre-screen leads against tort-specific criteria before they ever reach your team. That means the calls you receive should be faster, more productive, and more likely to convert.

When vetting a mass tort lead generation partner, look for:

• Clear, documented pre-qualification criteria specific to the tort you’re pursuing
• Transparency about lead sourcing and exclusivity — are you the only firm receiving that lead?
• A track record with the specific litigation category you’re targeting
• Predictable, trackable cost per case, not just cost per lead
• A compliance-conscious approach to advertising and outreach

A Word on Compliance

Mass tort advertising sits inside a genuinely complex compliance landscape. State bar advertising rules, TCPA requirements around outreach and consent, and tort-specific disclosure expectations all apply, and they vary by jurisdiction and by claim type. This guide is general marketing information, not legal or compliance advice. Any firm or vendor running mass tort campaigns should have qualified counsel review advertising and outreach practices for the specific states and torts involved.

Common Mistakes That Cost Firms Winnable Cases

Running generic “mass tort” ads instead of tort-specific ones. Vague messaging generates volume, not qualified claimants.

Ignoring statute of limitations urgency in messaging. Claimants who don’t understand the deadline they’re facing often wait too long to act — and lose a valid claim entirely.

Treating every lead source the same. Different channels and vendors produce dramatically different conversion rates. Lumping them together in your reporting hides which ones are actually worth the spend.

Underinvesting in intake speed. During active and settlement phases especially, the firm that responds fastest and most clearly often wins the case, regardless of which firm’s marketing reached the claimant first.

Frequently Asked Questions

How do I know if a mass tort lead generation vendor is worth the cost?

Look past cost per lead and evaluate cost per signed case. A vendor with documented, tort-specific pre-qualification criteria and a track record in your specific litigation category is worth more than a cheaper vendor generating high volumes of unqualified leads.

Which mass torts are generating the most leads right now?

As of 2026, GLP-1 weight-loss drug litigation, PFAS exposure claims, and social media harm claims are among the fastest-growing categories, alongside ongoing device litigation such as Bard PowerPort and Paragard.

Should my firm focus on one mass tort or several at once?

Most firms see better results by focusing marketing spend on one or two torts at a time, with clear expertise and intake readiness, rather than spreading the budget thin across many torts with generic messaging for each.

Why does litigation phase matter for marketing?

Cost per lead, competition, and claimant awareness all shift significantly as a case moves from pre-litigation to active litigation to settlement. Messaging and urgency need to match the phase, or campaigns will underperform relative to what the litigation stage would otherwise support.

Building a Mass Tort Practice That Scales

The firms winning the most cases in this environment aren’t necessarily spending the most on marketing. They’re the ones treating lead generation, qualification, and intake as one connected system instead of three separate problems. Match the right message to the right litigation phase, and move fast once a qualified claimant is identified.

Get those fundamentals right, and the rest of the work is simply staying disciplined about it as the litigation landscape keeps shifting.

Editor’s note: This post was originally published in November 2022 and has been substantially expanded and updated for 2026 with current MDL data, litigation-phase strategy, intake guidance, and vendor vetting criteria for attorneys.